Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease

Atherosclerosis

Volumn 219, Issue 2, 2011, Pages 892-899

  Urbonaviciene, Grazina ^a   Martin Ventura, Jose L ^b   Lindholt, Jes S ^a   Urbonavicius, Sigitas ^a   Moreno, Juan A ^b   Egido, Jesús ^b   Blanco Colio, Luis M ^b  

^a VIBORG HOSPITAL   (Denmark)

^b INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

Author keywords

Mortality; Peripheral artery disease; STWEAK

Indexed keywords

CD163 ANTIGEN; GLYCOPROTEIN; SOLUBLE TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CRITICAL LIMB ISCHEMIA; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INTERMITTENT CLAUDICATION; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; DENMARK; FEMALE; HUMANS; LOWER EXTREMITY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL ARTERIAL DISEASE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CELL SURFACE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR NECROSIS FACTORS;

EID: 82955167882     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.09.016     Document Type: Article

References (32)

1. Murabito J.M., Evans J.C., Nieto K., Larson M.G., Levy D., Wilson P.W. Prevalence and clinical correlates of peripherals artery disease in the Framinghan Offspring Study. Am Heart J 2002, 143:961-965.
2. Criqui M.H. Peripheral arterial disease - epidemiological aspects. Vasc Med 2001, 6(suppl.):3-7.
3. Cooke J.P., Wilson A.M. Biomarkers of peripheral arterial disease. J Am Coll Cardiol 2010, 55:2017-2023.
4. Ortiz A., Sanz A.B., Muñoz García B., et al. Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev 2009, 20:251-258.
5. Chicheportiche Y., Bourdon P.R., Xu H., et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997, 272:32401-32410.
6. Winkles J.A. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008, 7:411-425.
7. Kim S.H., Kang Y.J., Kim W.J., et al. TWEAK can induce proinflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 2004, 68:396-399.
8. Muñoz-García B., Moreno J.A., López-Franco O., et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 2009, 29:2061-2068.
9. Donohue P.J., Richards C.M., Brown S.A., et al. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003, 23:594-600.
10. Lynch C.N., Wang Y.C., Lund J.K., Chen Y.W., Leal J.A., Wiley S.R. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999, 274:8455-8459.
11. Bover L.C., Cardo-Vila M., Kuniyasu A., et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 2007, 178:8183-8194.
12. Kristiansen M., Graversen J.H., Jacobsen C., et al. Identification of the haemoglobin scavenger receptor. Nature 2001, 409:198-201.
13. Møller H.J., Peterslund N.A., Graversen J.H., Moestrup S.K. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 2002, 99:378-380.
14. Blanco-Colio L.M., Martín-Ventura J.L., Muñóz-García B., et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:916-922.
15. Kralisch S., Ziegelmeier M., Bachmann A., et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 2008, 199:440-444.
16. Carrero J.J., Ortiz A., Qureshi A.R., et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009, 4:110-118.
17. Jelić-Ivanović Z., Bujisić N., Spasić S., Bogavac-Stanojević N., Spasojević-Kalimanovska V., Kotur-Stevuljević J. Circulating sTWEAK improves the prediction of coronary artery disease. Clin Biochem 2009, 42:1381-1386.
18. Yilmaz M.I., Carrero J.J., Ortiz A., et al. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:1716-1723.
19. Chorianopoulos E., Rosenberg M., Zugck C., Wolf J., Katus H.A., Frey N. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur J Heart Fail 2009, 11:1050-1056.
20. Chorianopoulos E., Jarr K., Steen H., Giannitsis E., Frey N., Katus H.A. Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis 2010, 211:322-326.
21. Yilmaz M.I., Sonmez A., Ortiz A., et al. Soluble TWEAK and PTX3 in non-dialysis CKD patients; Impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol 2011, 6:785-792.
22. Moreno J.A., Dejouvencel T., Labreuche J., et al. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol 2010, 30:1253-1262.
23. Aristoteli L.P., Moller H.J., Bailey B., Moestrup S.K., Kritharides L. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 2006, 184:342-347.
24. Moreno J.A., Munoz-Garcia B., Martin-Ventura J.L., et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 2009, 207:103-110.
25. Joensen J.B., Juul S., Henneberg E., Thomsen G., Ostergaard L., Lindholt J.S. Can long-term antibiotic treatment prevent progression of peripheral arterial occlusive disease? A large, randomized, double-blinded, placebo-controlled trial. Atherosclerosis 2008, 196:937-942.
26. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1998, 44:837-845.
27. Martín-Ventura J.L., Lindholt J.S., Moreno J.A., et al. Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms. Atherosclerosis 2011, 214:486-489.
28. Yilmaz M.I., Carrero J.J., Martín-Ventura J.L., et al. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 2010, 5:1174-1181.
29. Harada N., Nakayama M., Nakano H., Fukuchi Y., Yagita H., Okumura K. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 2002, 299:488-493.
30. Muñoz-García B., Madrigal-Matute J., Moreno J.A., et al. TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovasc Res 2011, 89:225-233.
31. Schapira K., Burkly L.C., Zheng T.S., et al. Fn14-Fc fusion protein regulates atherosclerosis in ApoE-/- mice and inhibits macrophage lipid uptake in vitro. Arterioscler Thromb Vasc Biol 2009, 29:2021-2027.
32. Munoz-Garcia B., Martin-Ventura J.L., Martinez E., et al. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke 2006, 37:2044-2053.